Five systematic reviews and meta-analyses address the prognostic value of E-cadherin downregulation and loss of E-cadherin expression in head and neck cancer [98,229,230], oral cancer [82] and in oropharyngeal carcinoma [25]. This evidence concerns the gene CDH1 and oropharyngeal carcinoma.